Dolby Laboratories filings document the regulatory disclosures of a technology licensing and cinema-products company whose Class A common stock trades on the New York Stock Exchange under DLB. Recent Form 8-K reports furnish quarterly and annual financial results, dividend declarations for Class A and Class B common stock, and related exhibits.
The company’s proxy and governance filings cover director elections, advisory executive-compensation votes, auditor ratification and executive incentive compensation arrangements. The filings also describe Dolby’s dual-class voting structure, with Class A and Class B common stock voting together on most stockholder matters except where law requires otherwise.
Mark Andrew Sherman filed a notice under Rule 144 to sell 9,109 shares of DLB common stock. The planned sale, through Morgan Stanley Smith Barney on the NYSE, has an aggregate market value of $607,849.04 and is expected around 12/16/2025. For this class of stock, 60,845,846 shares were reported as outstanding.
The securities to be sold consist of restricted stock and performance shares acquired from the issuer on 12/15/2025. Over the prior three months, Sherman also sold 4,500 common shares on 12/01/2025, generating gross proceeds of $304,035.75.
Dolby Laboratories, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on February 3, 2026, including the election of eight directors, an advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor.
For fiscal 2025, Dolby reports total revenue of $1.35 billion versus $1.27 billion in 2024, a 6.3% increase, while net income was $255.0 million versus $261.8 million, a 2.6% decline. Non‑GAAP net income rose to $413.5 million and non‑GAAP diluted EPS to $4.24. Diluted EPS was $2.62, the year‑end share price was $72.39, and in November 2025 the quarterly dividend was raised 9%, from $0.33 to $0.36 per share.
The proxy describes a pay‑for‑performance program that kept named executive officer base salaries flat for 2025 and ties annual bonuses to revenue and non‑GAAP operating income. For fiscal 2025, non‑GAAP operating income of $447.5 million and revenue of $1,349.1 million produced payouts at 94% of target bonuses. Long‑term incentives are primarily equity awards, including performance stock units that vested at 70.37% of target for the 2022–2025 cycle based on relative total stockholder return.
Dolby Laboratories, Inc. executive John Couling, senior vice president of Entertainment, reported selling 7,273 shares of Class A common stock at $68.75 per share on 12/11/2025.
After this insider sale, he beneficially owned 108,065 Class A shares directly, including 48,526 shares underlying restricted stock units that are subject to forfeiture until they vest.
Dolby Laboratories, Inc. President and CEO Kevin Yeaman, who is also a director, reported option exercises and related share sales involving the company’s Class A common stock on 12/09/2025. Through the Kevin and Rachel Yeaman Family Trust, he exercised employee stock options for 10,615 shares at an exercise price of $64.6 and 23,752 shares at $45.5, then sold 28,168 shares at a weighted average price of $66.9919 and 6,199 shares at a weighted average price of $67.5052.
Following these transactions, the trust continued to hold Class A shares, and Yeaman also had 127,735 shares underlying restricted stock units that remain subject to vesting conditions, along with a small indirect holding reported as held by a son. The reported options were fully vested at exercise and now show no remaining derivative securities held through the trust.
An insider associated with DLB has filed a Form 144 notice to sell 7,273 shares of common stock through Morgan Stanley Smith Barney LLC on or about 12/11/2025 on the NYSE, with an indicated aggregate market value of $500,018.75. These shares were originally acquired as restricted stock from the issuer in three grants dated 08/10/2014, 12/15/2016, and 12/15/2018.
The notice also reports that 6,164 common shares were sold on 11/20/2025 for gross proceeds of $407,563.68. Shares of the issuer’s common stock outstanding were 60,845,846 as of the data shown; this is a baseline figure, not the amount being sold.
Dolby Laboratories shareholder plans new stock sale under Rule 144. A filing reports an intention to sell 34,367 shares of Dolby common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $2,305,493.01. Dolby had 60,845,846 shares of common stock outstanding.
The 34,367 shares were acquired on 12/09/2025 via a stock option exercise from the issuer, paid in cash on the same date. Over the past three months, the Yeaman Family Trust has sold additional Dolby common shares in three transactions of 36,699, 25,000, and 25,000 shares, generating gross proceeds of $2,455,401.64, $1,721,840.00, and $1,791,487.50, respectively.
Dolby Laboratories executive reports stock option exercise and sale. On 12/01/2025, EVP, General Counsel & Secretary Mark Andrew Sherman exercised an employee stock option for 4,500 shares of Dolby Class A common stock at an exercise price of $64.6 per share and acquired these shares.
On the same date, he sold 4,500 shares of Class A common stock at a weighted average price of $67.5635 per share in multiple transactions. Following these transactions, he beneficially owned 62,397 shares of Class A common stock, which include 45,470 shares underlying restricted stock units that remain subject to forfeiture until they vest.
Dolby Laboratories insider plans Rule 144 share sale. A holder has filed a notice to sell 4,500 shares of common stock of Dolby Laboratories under Rule 144. The proposed sale, through Morgan Stanley Smith Barney LLC on the NYSE, has an aggregate market value of $304,035.75 based on the filing information. The shares were acquired on 12/01/2025 via a stock option exercise from the issuer for cash, and the same number of shares is slated for sale. The filing notes that 60,845,846 shares of the issuer’s common stock were outstanding, providing context for the size of this planned transaction.
Dolby Laboratories, Inc. (DLB) President and CEO Kevin Yeaman, who is also a director, reported multiple transactions in Class A common stock and related stock options. On November 24, 2025, a family trust exercised employee stock options for 25,000 shares at $45.50 and 11,699 shares at $64.60, increasing indirect holdings. That same day, the trust sold 36,699 shares at a weighted average price of $66.9066, with the shares sold in multiple transactions under a Rule 10b5-1 trading plan adopted on February 28, 2025.
On November 26, 2025, Mr. Yeaman gifted 16,348 shares of Class A common stock from the trust to a donor-advised fund for charitable purposes. Following the reported transactions, indirect holdings include 98,377 shares in the family trust and additional indirect ownership through restricted stock units and shares held by a son.